Customer Publication

CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression

Authors: Ming Ji, Liyuan Wang, Ju Chen, Nina Xue, Chunyang Wang, Fangfang Lai, Rubing Wang, Shishan Yu, Jing Jin, Xiaoguang Chen

Journal: OncoTargets and Therapy (2022)

Research Areas: Cancer research

Cell Lines: T98G, U251 (Giloma cells)

Summary: Glioblastoma multiforme (GBM) is a malignant high-grade glioma with a poor clinical outcome. Temozolomide (TMZ) is the first-line GBM chemotherapy, yet patients commonly develop resistance to it. Therefore, the authors investigated the antitumor activity of CAT3 in TMZ-resistant glioblastoma cell lines U251/TMZ and T98G and demonstrated that CAT3 exhibited antitumor activity via blockade of the Hedgehog pathway and enhanced TMZ cytotoxicity in TMZ-resistant GBM. HoloMonitor M4 was used to measure the growth speed of two different TMZ-resistant glioblastoma cells.

Keywords: HoloMonitor M4, cell count, gli inhibitor, chemotherapy, lomeguatrib, xenograft tumor model

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
Sweden
+46 46 38 60 80
info@phiab.com

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
USA
+1 617-963-5150
info@phiab.com

Invoicing

VAT: SE556542781101
faktura@phiab.com

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2